Ventricular and atrial myocytes cultured from chick embryos 14 days in ovo were used as model systems to study cardiac adenosine receptors. In membranes of ventricular cultures, blocking of the A1-adenosine receptor pathway by the A1-selective antagonist 8-cyclopentyl-1,3 -dipropylxanthine (DPCPX) or by pertussis toxin treatment of the myocyte resulted in a significant adenosine agonist-mediated stimulation of the adenylate cyclase activity. The maximal increases in adenylate cyclase activity caused by the equipotent or the A2-adenosine receptorselective agonists (from 52.1±3% to 63±10% [mean±SEM]) were significantly greater than those caused by the A1-selective agonists (from 11+5% to 34.6+7%) (p<0.01, by t test, n=4-8). However, in membranes of atrial myocytes, when Al-subtype had been blocked, the various adenosine agonists had no effect on the adenylate cyclase activity. Whether the stiLmulatory adenylate cyclase-coupled adenosine receptor is also capable of stimulating contractility in the intact ventricular myocyte was next investigated. In ventricular but not in atrial cells, the various adenosine agonists caused an increase in the contractile amplitude in the presence of DPCPX or in myocytes preexposed to pertussis toxin. The increase in contraction amplitude caused by each agonist was expressed as percent of maximum (maximum is the increase in contractility, caused by 2.4 mM calcium). In the pertussis toxin-treated myocyte, the maximal increases caused by the equipotent or A2-agonists (NECA, MECA, CV-1808, and CGS21680, from 49.6+±3% to 52.5+6%, n=8-12) were significantly greater than those elicited by the Al-agonists (2-CADO, S-PIA, R-PIA, and DCCA, from 12±4% to 37+3%, n=8) (p<0.05, by t test). These data demonstrated that a stimulatory adenosine receptor, likely the A2-adenosine receptor, was present on the ventricular but not the atrial myocytes and was linked directly to a stimulation of the cardiac contractility. The functional effects mediated by the A1-subtype became manifested in the presence of isoproterenol, as evidenced by an inhibition of the isoproterenol-stimulated increases in adenylate cyclase activity and in cardiac contractility by adenosine agonists. Thus, both subtypes of adenosine receptors, each mediating opposing responses, were present on the ventricular myocytes, whereas only the A1-subtype was found in the atria. The presence of a stimulatory functional A2-adenosine receptor may help explain the absence of a direct negative inotropic response to adenosine in the ventricle. (Circulation Research 1992;70:56-65) In cardiac myocytes, the negative inotropic effect is mediated by adenosine receptors of the A1-subtype.1-3 In atria, the adenosine receptor agonist causes a direct, negative inotropic effect in the absence of a f3-adrenergic receptor agonist. How-
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In cardiac myocytes, the negative inotropic effect is mediated by adenosine receptors of the A1-subtype.1-3 In atria, the adenosine receptor agonist causes a direct, negative inotropic effect in the absence of a f3-adrenergic receptor agonist. How- ever, in ventricular myocytes, the negative inotropic effect of the adenosine receptor agonist is only evident when the myocyte contractility has first been stimulated by a 13-adrenergic agonist. In the absence of a ,3-adrenergic receptor agonist, adenosine or an adenosine agonist causes a slight increase or no increase in the contractility of the ventricular myocyte. In studies of the regulation of adenylate cyclase activity, adenosine agonists cause an inhibition of the cyclase activity stimulated by GTP or by isoproterenol in atria,1'3 whereas in the ventricles, the effects of adenosine agonists on cAMP level or on adenylate cyclase activity have been variable, with both an increased or a decreased level of the adenylate cyclase activity.4-6 Thus, the contractile and the adenylate cyclase responses of the ventricle to adenosine agonist differ from those of the atrium. The reason for the different contractile responses to adenosine between atria and ventricles was thought to be the coupling of the A1-adenosine receptor to a potassium channel in atria but not in ventricles. Another possibility was the presence of another subtype of adenosine receptor that mediated a stimulatory rather than an inhibitory effect on the adenylate cyclase and the cardiac contractility. Recent studies7-9 have demonstrated the presence of a separate subtype of adenosine receptor, the A2-adenosine receptor, that was coupled to an increase in the cAMP level in acutely dispersed ventricular myocytes from guinea pig and to a stimulation of the adenylate cyclase in membranes of ventricular myocytes cultured from adult rat or from chick embryo. These data were based on the ability of the equipotent agonist N-ethyladenosine-5'-uronic acid (NECA) to induce an increase in cAMP level or in adenylate cyclase activity in the presence of the A1-adenosine receptor-selective antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX). However, a pharmacological characterization of this stimulatory adenosine receptor subtype and the relative roles of the stimulatory and the inhibitory adenosine receptor subtypes in modulating the GTP basal and the isoproterenolstimulated adenylate cyclase activity has not been carried out. Further, although the ability of NECA to inhibit the isoproterenol-stimulated increase in contractility was partially reversed by an A1-selective antagonist,8 it is not known whether the presence of an A1-antagonist will unmask a stimulatory effect of NECA on the basal contractile state in the absence of isoproterenol. It is not clear whether the A2-subtype has a functional role in modulating the contractility of the ventricular myocyte and whether the presence of the A2-subtype in ventricles could help explain the ventricular contractile response to adenosine. In the present study, atrial and ventricular myocytes cultured from chick embryos, in which the A1-adenosine receptor can be blocked by DPCPX or uncoupled from its functional effect(s) by pertussis toxin (PTX) treatment of the culture,3 were used to 1) investigate whether activation of a different subtype of the adenosine receptor, which could mediate a stimulation of the adenylate cyclase, is capable of stimulating or modulating the cardiac contractility and 2) carry out pharmacological characterization of this adenosine receptor subtype. A further objective of the present study was to test the notion that these stimulatory adenosine receptors are preferentially expressed on the ventricular but not the atrial myotricular myocytes, adenosine receptor agonists, whether selective for the Al-or the A2-subtypes or equipotent, were all capable of causing an increase in the myocyte contractility as well as in the adenylate cyclase activity when the A1-adenosine receptor pathway had been blocked by either DPCPX or PTX. Both adenosine receptor subtypes coexisted on the ventricular myocyte, and each subtype mediated opposing functional responses, whereas only the A1-subtype was present on the atrial myocyte. 
Materials and Methods
-R-phenyl-2-propyladenosine (R-PJA), N6-S-phenyl-2-propyladenosine (S-PIA), DPCPX, NECA, 8-(p-sulfophenyl)theophylline (8-PST), N-methyladenosine-5'-uronic acid (MECA), 2-chlo- roadenosine (2-CADO), 2-phenylaminoadenosine (CV-1808), 2-[p-(2-carboxyethyl)-phenethylamino]-
Methods
Tissue preparation. Atrial and ventricular myocytes from chick embryos 14 days in ovo were maintained in culture as previously described. Contractility. Measurement of contractile amplitude in cultured atrial and ventricular myocytes was performed with an opticovideo motion detection system as previously described.3'112 The cultured heart cells attached on a glass coverslip were placed in a perfusion chamber with temperature maintained at 37°C. The chamber was placed on the stage of an inverted phase-contrast microscope (Nikon) with both an inlet and an outlet that allowed infusion and removal of medium containing the various drugs. The contractile motion of attached cells was monitored by an opticovideo motion detecting system as previously described12 using a video motion analyzer (Colorado Video, Boulder, Colo.). The perfusion medium contained the following (mM): HEPES 4 (pH 7.4), NaCI 137, KCl 3.6, MgCl2 0.5, CaCl2 0.6, glucose 5.5, and horse serum at 6% as well as the various drugs at the indicated concentrations. The mean+SEM rate of contraction was 135 ± 14 beats per minute (n = 104). The mean±SEM increase in contractile amplitude produced by raising the calcium concentration from 0.6 to 2.4 mM in the superfusion medium was 46.8±3.1% (n=50) and represented the maximal increase in contraction amplitude. The increase in the contraction amplitude by each agonist was normalized to the increase caused by 2.4 mM calcium as percent maximum. osine-5'-uronic acid; MECA, N-methyladenosine-5'-uronic acid; CV-1808, 2-phenylaminoadenosine; CGS21680, 2 [p-(2-carboxyethyl)-phenethylamino-5 '-N-ethylcarboxamido adenosine; 2-CADO, 2-chloroadenosine; S-PIA, N6-S-phenyl-2-propyladenosine; R-PIA, N -R-phenyl-2-propyladenosine; DCCA, 1-deaza-2-chloro-N6-cyclopentyladenosine. Cultured ventricular myocytes were preexposed to pertussis toxin (5 ng/ml for 12 hours), and assay of adenylate cyclase activity was carried out in the presence of the agonists indicated as described in "Methods." The values for the percent increase in adenylate cyclase caused by the equipotent or the A2-agonists were similar to one another (by one-way analysis of variance, F-0.034,p=0.9912) but were significantly greater than values for the percent increase stimulated by the Al-agonists (p<0.01, unpaired t test comparing each pair of the A1-and A2-agonists). GTP was present at 100 jiM, and each analogue was also present at 100^M . one another except among the R-PIA versus S-PIA and the R-PIA versus DCCA comparisons (ANOVA followed by group comparisons, the difference was significant at the 95% confidence level). The stimulation of adenylate cyclase activity in these PTXtreated ventricular cells was blocked by the presence of 8-PST (300 gM) (data not shown), indicating that the increase in adenylate cyclase was secondary to activation of an adenosine receptor. These data suggest that a stimulatory adenosine receptor subtype, distinct from the inhibitory Al-subtype, was also present on the cultured ventricular myocyte. Parallel studies were carried out in membranes prepared from cultured chick atrial myocytes. In contrast to the ventricular myocyte, the various adenosine receptor agonists inhibited the GTP-mediated adenylate cyclase activity in membranes prepared from atrial cells, consistent with previous findings.3 The inhibition was abolished by A1-selective antagonist DPCPX (0.3 ,uM). Further, the various adenosine agonists did not elicit an increase in the adenylate cyclase activity in the presence of DPCPX (Table 2 ). These data suggest that, in atria, a stimulatory adenosine receptor was not present and that the predominant adenosine receptor was of the inhibitory Al-subtype.
Modulation ofAdenylate Cyclase Activity by
Activation of the Al-and the A2-Adenosine
Receptors in Ventricles
To investigate the role of each adenosine receptor subtype in modulating the adenylate cyclase activity in these myocytes, the effects of adenosine receptor agonists on the adenylate cyclase activity in the presence or the absence of isoproterenol were examined. In membranes of ventricular myocytes, the adenosine agonists (either A1-or A2-selective) caused a slight stimulation of the adenylate cyclase activity in the absence of isoproterenol (Table 2) ; the extent of stimulation, however, could be markedly enhanced in the presence of DPCPX or in PTX-treated myocytes (Tables 1 and 2 ). These data suggested that an A1-adenosine receptor-mediated inhibition was normally present when DPCPX or PTX was not used. In the presence of isoproterenol, the adenosine receptor agonists caused an inhibition of isoproterenol-stimulated adenylate cyclase activity (Table 3 ). The inhibitory nature of the response elicited by the adenosine agonist indicated an involvement of the A1-adenosine receptor, similar to a previous finding.3 Prior treatment of the cell with PTX abolished this adenosine agonist-induced inhibition (Table 4) , providing fur- ther evidence that the A1-adenosine receptor mediated the antagonism of isoproterenol-stimulated adenylate cyclase activity. Thus, in ventricles, adenosine agonists activated both the inhibitory A1-and the stimulatory A2-receptors under the basal condition, resulting in a slight overall stimulation of the adenylate cyclase. In the presence of isoproterenol, however, activation of the A1-subtype was able to cause an inhibition of the isoproterenol-stimulated increase in the adenylate cyclase activity.
Stimulation of Ventricular Contractility by the Adenosine Receptor Agonist
We next examined whether the A2-adenosine receptor was also capable of coupling to a stimulation of the myocardial contractility. The various adenosine receptor agonists tested, whether A1-or A2-selective or equipotent, caused a significant increase in the cardiac contractility when the inhibitory A1-adenosine receptor pathway had been blocked by sine; 2-CADO, 2-chloroadenosine; S-PIA, N6-S-phenyl-2-propyladenosine; R-PIA, N6-R-phenyl-2-propyladenosine; DCCA, 1-deaza-2-chloro-N6-cyclopentyladenosine. Cultured ventricular cells were preexposed to pertussis toxin (5 ng/ml for 12 hours), and the contractile response to the various agonists was determined as described in "Methods." The contractile amplitude under the control condition before infusion of the adenosine agonists was 1.23±0.25 gtm (n=32). The increase in contractile amplitude caused by the adenosine agonists (100 ,uM) was normalized to the increase produced by 2.4 receptor was also present on atrial myocytes, we carried out parallel studies to determine whether adenosine receptor agonists were able to stimulate the cardiac contractility in the presence of the Aladenosine receptor-selective antagonist DPCPX. None of the adenosine receptor agonists tested, whether A1-or A2-selective or equipotent, could induce an increase in the cardiac contractility in the presence of DPCPX in the atrial myocytes ( Figure 5) . Similarly, in PTX-treated atrial culture where the A1-adenosine receptor was uncoupled from its functional effects, NECA (100 ptM) failed to stimulate any increase in the contractile amplitude (control amplitude, 1 -Log [Agonist] FIGURE 4. Graph showing effects of varying concentrations of adenosine receptor agonists on the contractile amplitude in pertussis toxin -treated ventricular myocytes. NECA, N-ethyladenosine-5'-uronic acid; MECA, N-methyladenosine-5'-uronic acid; R-PIA, N6-R-phenyl-2-propyladenosine; 2-cADO, 2-chloroadenosine; S-PL4, N6-S-phenyl-2-propyladenosine. Ventricular myocytes pretreated with pertussis toxin (5 ng/ml for 12 hours) were exposed to varying concentrations of each agonist, and the amplitude of cell motion was measured as described in "Methods." The increase in the contractile amplitude produced at each concentration of the agonist was normalized to the increase in contractile amplitude caused by 2.4 Tracings of the steady state for each condition were presented and were typical of six other similar experiments.
The Role ofAdenosine Receptor Subtypes in Modulating the Contractile State of the Ventricular Myocyte To investigate the possible coexistence of the inhibitory A1-and the stimulatory A2-adenosine receptors on the ventricular myocyte and to study their potential roles in modulating the cardiac contractility, the effects of various agonists on the myocardial contractility in the presence or the absence of isoproterenol were investigated. In the absence of isoproterenol, the adenosine agonists (100 gM) caused a slight stimulation of the contractility (from 6.6+±3% to 18+4%, n=8-10, where increase in contractility is percent of maximum contractility produced by 2.4 mM calcium). The degree of the adenosine agonistinduced increase in the contractile amplitude, however, was significantly enhanced in the presence of DPCPX or in PTX-treated cells ( Figure 3, Table 5 ), indicating the presence of an inhibitory effect mediated by the A1-adenosine receptor when DPCPX or PTX was not used. In the presence of isoproterenol, the agonists caused a significant inhibition of the increase in contractility produced by isoproterenol ( Figure 6 ). abolished the adenosine agonist-induced inhibition, indicating that the A1-adenosine receptor mediated the antagonism of isoproterenol-stimulated increase in contractility (Table 4 and Figure 6 ).
Discussion
The myocardial depressant effects of adenosine are mediated by adenosine receptor of the A1-subtype.1-3 Whereas adenosine agonist induces a direct negative inotropic effect in the atrial cell, it is capable of inducing a negative inotropic effect in the ventricular cell only after the myocyte contractility has been stimulated by a cAMP-raising agent. The reason for the difference in contractile response to the adenosine receptor agonist between atrial and ventricular myocytes is thought to be the activation of a potassium channel by adenosine in atria with a consequent abbreviation of the action potential duration and the duration of calcium influx.1"616"7 Recent studies7-9 have demonstrated that a separate subtype of the adenosine receptor coupled to stimulation of adenylate cyclase was present in ventricles. These data raised the possibilities that the stimulatory adenosine receptor may be preferentially present in ventricles but not in atria and that this preferential expression of the stimulatory adenosine receptor, opposing the inhibitory A1-adenosine receptor, may also explain the lack of a direct negative inotropic effect of adenosine in the ventricular myocyte. However, it is not clear whether the stimulatory adenylate cyclasecoupled adenosine receptor is able to couple to a stimulation of the ventricular contractility, which could serve to counteract the inhibition of contractility mediated by the A1-adenosine receptor. Our preliminary data9 suggested that in membranes of ventricular myocytes cultured from chick embryos, a distinct subtype of the adenosine receptor was present and was coupled to an increase in the adenylate cyclase activity. The objective of the present study, using cultured chick cardiac myocytes as a model system, is to further characterize pharmacologically the stimulatory adenylate cyclase-coupled adenosine receptor and to test the hypotheses that these adenosine receptors are capable of coupling to an increase in the contractility of the ventricle and are present only on ventricular but not on atrial cells.
To unmask the functional effects mediated by the stimulatory adenosine receptor, we used two methods to inactivate the inhibitory A1-adenosine receptor pathway. The first method used PTX to uncouple the A1-adenosine receptor from its inhibitory effect on the adenylate cyclase activity and the myocyte contractility. The second method involved blocking the inhibitory A,-adenosine receptor by a highly selective A1-adenosine receptor antagonist, DPCPX. In the pharmacological characterization of these A2-adenosine receptors, a potential advantage of using PTX treatment to inactivate the A,-adenosine receptor pathway is the ability of PTX to uncouple all inhibitory receptors including possible subtype(s) of the A1-adenosine receptor that may not be blocked by DPCPX. The second possible benefit of using PTX rather than DPCPX is that, at the high concentration of the adenosine agonist, 0.3 /.M DPCPX may not be adequate in blocking all the A1-adenosine receptors. Adenosine receptor agonists had a slight stimulatory effect on the GTP-dependent basal adenylate cyclase activity in membranes of cultured ventricular myocytes. Prior treatment of the cultured ventricular cell with PTX led to markedly greater increases in the extent of stimulation of the adenylate cyclase by these agonists. Blocking of the A,-adenosine receptor by the A,-selective antagonist DPCPX also resulted in a significant increase in the abilities of the various adenosine receptor agonists to stimulate adenylate cyclase activity. These data indicate the presence of a stimulatory effect of adenosine agonists on the adenylate cyclase activity, which became manifested by the uncoupling of A,-adenosine receptors from the cyclase. Thus, in ventricles, a different subtype of the adenosine receptor is present and couples, in a stimulatory rather than an inhibitory fashion, to the adenylate cyclase. The potency of the R-PIA effect on the adenylate cyclase activity in these PTX-treated cells was similar to the potency of NECA or S-PIA, indicating that the receptor subtype involved is not the A.-adenosine receptor. The cou-pling of this subtype of adenosine receptor to a stimulatory adenylate cyclase response suggested that the subtype was the A2-adenosine receptor.
The similarity in the potency of the adenosine agonists in stimulating the adenylate cyclase is in contrast to the classical rank order of potency described for the effects mediated by the A2-adenosine receptor. The reason for such a difference is not known but may be related to the heterogeneity of the A2-adenosine receptors18,19 or to the differences between the coupling of the A2-adenosine receptor to adenylate cyclase in these cultured ventricular myocytes. An alternative explanation is that the relatively small magnitude of increase in the adenylate cyclase activity makes it difficult to obtain and compare accurately the difference in EC50 for each agonist. It is curious that the A2-selective or the equipotent agonists were capable of causing a greater stimulation of the adenylate cyclase activity than were the A1-adenosine receptor-selective agonists. Taken together, these experiments provide direct evidence that a separate subtype of the adenosine receptor, probably of the A2-subtype, is present and is coupled to a stimulation of the adenylate cyclase activity in the ventricular myocyte.
Prior studies by others8 demonstrated that the nonselective agonist NECA was capable of stimulating an increase in the cAMP level in guinea pig ventricular myocytes in the presence of DPCPX. The increase in the cAMP level elicited by NECA in the presence of DPCPX represented a further increase in the cAMP level, above that produced by isoproterenol. This NECA-induced increase in the cAMP level was associated, however, with a NECA-mediated inhibition of the contractility stimulated by the same concentration of isoproterenol. The reason for the discrepancy between the NECA effects on the cAMP level and the myocyte contractility is not clear but may be related, perhaps, to compartmentalization of intracellular cAMP, as suggested by Behnke et al. 8 An issue that was not addressed in the previous study8 relates to the question of whether activation of the A2-subtype is capable of stimulating the basal contractile state of the ventricle in the absence of f3-adrenergic stimulation. In the present study, we examined whether the adenosine receptor agonists, under conditions that caused a stimulation of the adenylate cyclase activity, were also capable of eliciting an increase in the basal contractility of the cultured chick ventricular myocyte. Because these ventricular cells contract spontaneously, they afford a unique opportunity to investigate the modulation of ventricular contractile state by adenosine. In contrast to the atrial myocyte, in which adenosine agonists caused a direct negative inotropic effect, the same agonists produced a slight increase in the cardiac contractility in the ventricular myocyte. In ventricular but not in atrial cells, blocking of the A1-adenosine receptor by DPCPX or uncoupling of the A1-adenosine receptor from its effector(s) by PTX resulted in a further significant increase in contractile amplitude in response to adenosine or adenosine agonists. Thus, a separate subtype of the adenosine receptor is present on the ventricular myocyte and is coupled to stimulation of the myocardial contractility, in parallel with a stimulation of the adenylate cyclase activity.
The EC50s for each agonist-induced stimulation of the myocyte contractility were all similar, consistent with the similarity of the EC50s of these agonists in stimulating the adenylate cyclase activity. The maximal increases in contractile amplitude produced by the A2-adenosine receptor-selective or equipotent agonists were significantly greater than those evoked by the A1-adenosine receptor agonists, also similar to the findings on the maximal stimulation of adenylate cyclase by these agonists. These data are compatible with the possibility that the subtype of adenosine receptor, the A2-adenosine subtype, that mediated the stimulation of myocyte contractility was the same subtype that mediated the stimulation of adenylate cyclase activity. Since the cultured heart cell preparation contains fibroblasts (<7%),20 the present study cannot rule out the possibility that the stimulation of adenylate cyclase activity by the adenosine agonist is partially due to activation of the A2-subtype present in membranes of the fibroblasts in the ventricular culture. However, such a possibility is unlikely, because the atrial culture, which also contained fibroblasts, did not exhibit any adenosine agonist-induced stimulation of adenylate cyclase activity or cardiac contractility.
To investigate the potential role of each subtype in modulating the adenylate cyclase activity and the cardiac contractility of the ventricular cell, the abilities of adenosine agonists to regulate the basal and the isoproterenol-stimulated responses were examined. Under the basal condition in the absence of isoproterenol, adenosine agonists caused a slight increase in the adenylate cyclase activity, with a concomitant stimulation of the cardiac contractility. Blocking of the A1-adenosine receptor resulted in a markedly enhanced stimulation of these two responses by the adenosine agonist. These results demonstrate that the A2-adenosine receptor-mediated stimulatory effects are masked by the inhibitory effects of the A1-subtype. These data raised the possibility, although speculative, that the inhibitory contractile effect mediated by the A1-adenosine receptor was counterbalanced by the positive stimulatory effect of the A2-adenosine receptor in response to adenosine, which could activate both receptor subtypes. In the presence of isoproterenol, adenosine agonists caused an inhibition of the isoproterenolstimulated increase in adenylate cyclase activity and in myocyte contractility, an effect mediated by the Al-subtype. These data are compatible with those of Behnke et al,8 which demonstrated an inhibition of isoproterenol-stimulated increase in contractile amplitude by both the equipotent agonist NECA and the A1-selective agonist R-PIA, an inhibition that was antagonized by the A1-selective antagonist DPCPX. The present data on the ventricular myocyte are in contrast to the findings in the atrial myocyte, in which adenosine agonists have a marked inhibitory effect on contractility and on the adenylate cyclase activity regardless of whether isoproterenol is present. The cardiac contractile and adenylate cyclase responses to adenosine appear to correlate with the presence (ventricles) or the absence (atria) of the A2-adenosine receptor. The present study thus raises the possibility that the ability of adenosine agonists to modulate adenylate cyclase activity or myocardial contractility is a function of the activation of a particular adenosine receptor subtype, the expression of which is atrium and ventricle specific.
Taken together, these results indicate that both the A1-and the A2-subtypes of the adenosine receptor are present on the ventricular myocyte and that each subtype mediates opposing biochemical and physiological responses, whereas only the Al-subtype is present on the atrial myocyte. The absence of the stimulatory A2-adenosine receptor subtype on the atrial cell, in addition to the ability of the atrial A1-adenosine receptor to couple to a potassium channel, may help explain the ability of adenosine to cause a direct negative inotropic effect in the atrium. It is not known at the present time whether the stimulatory A2-receptor in the embryonic chick ventricular cell is similar to the A2-adenosine receptor in the adult mammalian heart cell. Nevertheless, the presence of both adenosine receptor subtypes, which are functionally coupled to cardiac responses in these cultured ventricular myocytes, suggests that these cultures may be a good model system for the study of cardiac adenosine receptors.
